Patent Application Attorney Docket No.10334A

by certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed : Assistant Commissioner for Patents, Washington, D.C Jon this 4TH day of OCTOBER, 2001. By e of person mailing) OCT 1 1 2001 AYMÒND M. SPEER, REG. NO. 26,810 (Typed or printed name of person) TECH CENTER 1600/2900 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE IN RE APPLICATION OF: MONAGHAN, ET AL. **APPLICATION NO.: 09/590,585** Examiner: --FILING DATE: **JUNE 8, 2000** Group Art Unit: --TITLE: **PURINE DERIVATIVES Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Oct. 4 200

Attorne for Applicants

Reg. No. 26,810

Pfizer Inc Patent Department, 150-5-49 235 East 42nd Street New York, NY 10017-5755 (212) 733-4606

USERS\DOCS\LA21952\LPRMS\3@PQ01!.DOC / 153854 INFORMATION DISCLOSURE STATEMENT, 3/99, (1/1)